3Grundmann H, Barwolff S, Tami A, et al. How many infections are caused by patient-to-patletnt transmission in intensive care units? Crit Care Med ,2005,33 ( 5 ) :946 - 951.
4Serralta VV, Harison-Belestra C, Cazzaniga AL, et al. Lifestyles of bacteria in wounds: presence of biofilms? Wounds, 2001, 13 (1) :29 -34.
5Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign-guidelines for management of severe sepsis and septic shock. Intensive Care Med, 2004,30 (4) :536 - 555.
6Sobieszczyk ME,Furuya EY,Hay CM,et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicreb Chemother, 2004,54 (2) :566 - 569.
7Falagas ME ,Bliziotis IA, Kasiakou SK, et al. Outcome of infection due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis, 2005,5( 1 ) :24.
8Saliba MJ Jr. Heparin in the treatment of burns: a review. Burns, 2001,27 (4) :349 - 358.
9Diehl JL,Borgel D. Sepsis and coagulation. Curr Opin Crit Care, 2005,11 ( 5 ) :454 - 460.
10van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med ,2001,345 (19) :1359 -1367.
